XML 33 R23.htm IDEA: XBRL DOCUMENT v3.19.1
Significant Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended
Jan. 31, 2019
Feb. 28, 2017
Mar. 31, 2015
Jun. 30, 2010
Mar. 31, 2019
Dec. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Equity investment fair value amount         $ 56,400 $ 0
Voyager Therapeutics | Collaboration and License Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Up-front cash payable $ 115,000          
Collaborative agreement equity investment amount $ 50,000          
Share price $ 11.9625          
Equity investment fair value amount $ 54,700          
Collaboration termination notice period         180 days  
Voyager Therapeutics | Collaboration and License Agreement | IPR&D            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Collaborative agreement remaining purchase price $ 113,100          
Voyager Therapeutics | Collaboration and License Agreement | Common Stock            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Common stock issued for collaboration agreement 4.2          
Voyager Therapeutics | Collaboration and License Agreement | Development, Regulatory and Commercial Milestone Payment            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Potential milestone payments $ 1,700,000          
B I A L            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Up-front license fees   $ (30,000)        
B I A L | Development and Regulatory Milestone Payments            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Collaborative agreement maximum additional payment to receive         $ 40,000  
Collaborative agreement payment received         10,000  
B I A L | Commercial Milestone Payments            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Collaborative agreement maximum additional payment to receive         75,000  
Mitsubishi Tanabe            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Up-front license fees     $ 30,000      
Collaborative agreement maximum additional payment to receive     85,000      
Revenues recognized under collaboration agreement     19,800      
Deferred revenues under collaboration     10,200      
Mitsubishi Tanabe | Phase II/III Clinical Trials            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Revenues recognized under collaboration agreement     $ 15,000      
AbbVie            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Up-front license fees       $ 75,000    
AbbVie | Development and Regulatory Milestone Payments            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Collaborative agreement maximum additional payment to receive         480,000  
Collaborative agreement payment received         115,000  
AbbVie | Commercial Milestone Payments            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Collaborative agreement maximum additional payment to receive         $ 50,000